Company News
12 Jun 2026
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales, Tommy Hall and PHASE Scientific's VP of Commercial Operations, Bob Gergen recently discussed how the Company strengthening its market footprint since receiving FDA CLIA waiver clearance for FebriDx in March 2026.
A few more pieces along the same thread. See the full index for everything.
COMPANY NEWS
2 min read
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
COMPANY NEWS
1 min read
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...
COMPANY NEWS
1 min read
Following the success of their initial program and supported by the recent granting of CLIA waiver for FebriDx®, WellStreet has now begun testing at 43 additional sites...